Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is an open-label, non-interventional study to evaluate efficacy and safety in rheumatoid arthritis participants receiving tocilizumab as per the product label.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Rheumatoid arthritis participants | Rheumatoid arthritis participants receiving tocilizumab intravenous infusion every 4 weeks according to product label/per standard practice for a maximum of 12 months will be observed in this study. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Tocilizumab | Drug | Tocilizumab administered as an intravenous infusion every 4 weeks according to product label/per standard practice for a maximum of 12 months will be observed in this study. |
| Measure | Description | Time Frame |
|---|---|---|
| Disease Activity Score Based on 28-joints Count (DAS28) | Month 12 | |
| Simplified Disease Activity Index (SDAI) Score | Month 12 | |
| Clinical Disease Activity Index (CDAI) Score | Month 12 | |
| Percentage of Participants Achieving American College of Rheumatology (ACR) Response | Month 12 | |
| Tender Joint Count (TJC) | Month 12 | |
| Swollen Joint Count (SJC) | Month 12 |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants with any Adverse Event (AE) | Up to 36 months |
Not provided
Inclusion Criteria:
- Participants with rheumatoid arthritis receiving tocilizumab as per product label
Exclusion Criteria:
- No specific exclusion criteria were specified for this non-interventional trial
Not provided
Not provided
Not provided
Not provided
Participants with rheumatoid arthritis will be enrolled in this trial.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Trials | Hoffmann-La Roche | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Bludenz | 6700 | Austria |
Not provided
| ID | Term |
|---|---|
| D001172 | Arthritis, Rheumatoid |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C502936 | tocilizumab |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| D003240 |
| Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |